Contact
Please use this form to send email to PR contact of this press release:
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
TO:
Please use this form to send email to PR contact of this press release:
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
TO: